The drug, tolebrutinib, delayed disability progression by 31% in people with a type of MS called non-relapsing secondary progressive multiple sclerosis, researchers reported in the New England Journal ...
Roche Holdings AG RHHBY on Monday shared new late-breaking data from the Phase 3 FENtrepid study of the investigational ...
—Clinicians may be underestimating the cognitive burden on patients with MS, underscoring the need for more comprehensive cognitive assessments and assessing patient-reported outcomes. A growing body ...
To provide the right treatment for multiple sclerosis (MS), it is important to know when the disease changes from relapsing-remitting to secondary progressive, a transition that is currently ...
Researchers from Kyushu University have identified a potential therapeutic target for the treatment of advanced multiple sclerosis (MS), a potentially disabling condition associated with the central ...
Biosimilar natalizumab (Tyruko) is approved by EMA, US FDA, MHRA etc. and article is intended only for the HCP audience in ...
Multiple sclerosis B-cell profiles differ by ancestry and sex among Black and Hispanic patients with multiple sclerosis.
Nearly 1 million people in the United States have MS, and there’s a thriving community of like-minded people dedicated to finding a cure and helping people live their best life while managing the ...
Music activates multiple parts of the brain. For people with MS, a choir is exploring what singing together can offer.
An experimental drug can help patients with advanced multiple sclerosis delay the progressive disability that comes with their disorder, a new clinical trial suggests. The drug, tolebrutinib, delayed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results